Navigation Links
Study Finds Nearly One-Third of All Inexpensive Earrings Examined Tested Positive for Nickel
Date:5/12/2008

exposure."

Dr. Maibach added that in one accessory store, none of the 44 earrings priced between $5 and $8 were DMG positive, whereas numerous earrings priced between $15 and $25 in another accessory store were DMG positive.

"From our findings, we could not establish a 'safe-limit price' as a guide for consumers who want to avoid excessive nickel exposure when purchasing inexpensive earrings," said Dr. Maibach. "But it's safe to say that young customers purchasing earrings at a considerable price range in U.S. chain stores are potentially at risk of nickel exposure and sensitization."

Studies show that nickel sensitization increases the risk of hand eczema, but Dr. Maibach argued that avoiding nickel -- which is found almost everywhere -- can be difficult. He acknowledged that there are some patients with nickel dermatitis who refuse to give up their jewelry, even when they know it is the cause of their condition. Since the best way to avoid nickel sensitization and subsequent dermatitis is to prevent nickel exposure, Dr. Maibach suggested the following tips:
-- Look for jewelry and clothing labeled "nickel-free" or "hypoallergenic"

-- Wear only stainless steel, platinum or gold jewelry if you know you are

allergic to nickel

-- Discontinue wearing jewelry that causes any noticeable skin irritation,

such as redness or itching

-- Use 1% hydrocortisone cream or ointment, which can be purchased

over-the-counter, to treat nickel-induced dermatitis

-- See your dermatologist if symptoms worsen or do not improve within

three to five days of not wearing jewelry

Headquartered in Schaumburg, Ill., the American Academy of Dermatology (Academy), founded in 1938, is the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 15,000 physicians worldwide, the Academy is committed to: advancing the diagnosis and medical, surgi
'/>"/>

SOURCE American Academy of Dermatology
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal
2. New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health
3. Study finds link between birth order and asthma symptoms
4. Study Offers Clues to Link Between Arrhythmia, Sudden Death
5. Study affirms effectiveness of medication for juvenile rheumatoid arthritis
6. Study identifies molecular response of cartilage to injury
7. Skin flaps deliver cancer-fighting therapy, ASPS study reveals
8. Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)
9. MIT study suggests caution on new anti-obesity drug in kids
10. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
11. Study in mice suggests molecules in plants have beneficial effect on Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Moravia Worldwide to Present Live Webinar on Creation and Use of Terminology in Localization 2Health News:Moravia Worldwide to Present Live Webinar on Creation and Use of Terminology in Localization 3Health News:Lung Cancer Alliance Praises Growing National Coalition 2Health News:Lung Cancer Alliance Praises Growing National Coalition 3Health News:Book Offers Help for Parents Struggling with Difficult Teens During the Upcoming Holidays 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Procter & Gamble Announces Appointment of Director 2
Breaking Medicine Technology:Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 1Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 2Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 3Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 4Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 1Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 2Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 3Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 4Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 1Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 2Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 3
Other Medicine Technology:Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 4Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 5Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 2Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 3Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 4Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 5Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 6Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 7